Sorrento Therapeutics Mexico (“Sorrento Mexico”) and INMEGEN have executed an MOU to further collaborate on clinical development of a broad pipeline of COVID products, including diagnostics, multivalent mRNA-based vaccines and therapeutics. Sorrento provides its most comprehensive portfolios and a “one-stop-shop" of potential solutions for governments interested in a multi-modal “detect and treat” approach to the COVID-19 pandemic.
Sorrento Mexico plans to install local clinical research and development capabilities within the INMEGEN facilities and personnel in Mexico City and will work closely with Mexican hospitals and clinical institutions on clinical protocols, regulatory registration and approval requirements for the COVID-19 product development.
SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that its subsidiary company, Sorrento Therapeutics Mexico (“Sorrento Mexico”), has entered into an MOU agreement with the National Institute of Genomic Medicine INMEGEN (“Instituto National de Medicine Genomica”) to cooperate in the development, testing and support of multiple COVID-19 related products Sorrento plans to commercialize in Mexico.
Sorrento Mexico and INMEGEN will expand its collaboration to include additional Sorrento COVID pipeline products spanning diagnostics, therapeutics and multivalent vaccines, including the following product candidates:
COVITRACK™: COVID-19 antibody detection diagnostic test for vaccinated people;STI-2020 (COVI-AMG™): Affinity matured neutralizing antibody against SARS-CoV-2 for outpatient COVID patients;STI-2099 (COVIDROPS™): Intranasal neutralizing antibody version of COVI-AMG for newly diagnosed COVID patients;COVISHIELD™: Cocktail of neutralizing antibodies against variants of concern of SARS-CoV-2;STI-5656 (Abivertinib): BTK inhibitor for the treatment of acute respiratory distress syndrome (ARDS) in hospitalized COVID patients;STI-8282 (COVI-MSC™): Allogeneic mesenchymal stem cells for the treatment of COVID-associated ARDS in severe COVID patients; andMultivalent mRNA Vaccines: mRNA-based multivariant vaccines protecting against SARS-CoV-2 virus, Alpha, Beta, Delta and Gamma variants of concern.
Sorrento Mexico plans to establish a local research laboratory within INMEGEN’s facilities to ensure close collaboration between the INMEGEN and Sorrento teams for testing, clinical trials and development of COVID related products.
“We are excited about our close collaboration with INMEGEN and intend to have Sorrento Mexico as a gateway to all Latin American countries for our innovative COVID diagnostic, vaccine and therapeutic product candidates,” said Henry Ji, Ph.D., Chairman and CEO of Sorrento Therapeutics.
